original article 
June 2, 2012 | S.L. Topalian
and Others
(DOI: 10.1056/NEJMoa1200690)
and Others
(DOI: 10.1056/NEJMoa1200690)
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint molecule, programmed death 1 (PD-1), has also shown activity against cancers, including non–small-cell lung cancer.
- Comments